| Patient-centered communication: do patients really prefer it? SL Swenson, S Buell, P Zettler, M White, DC Ruston, B Lo Journal of general internal medicine 19, 1069-1079, 2004 | 409 | 2004 |
| Food and drug law PB Hutt, RA Merrill, LA Grossman, N Cortez, EF Lietzan, PJ Zettler Foundation Press, 2022 | 291 | 2022 |
| ISSCR guidelines for stem cell research and clinical translation: the 2021 update R Lovell-Badge, E Anthony, RA Barker, T Bubela, AH Brivanlou, ... Stem cell reports 16 (6), 1398-1408, 2021 | 184 | 2021 |
| Pharmaceutical Federalism PJ Zettler Ind. LJ 92, 845, 2016 | 109 | 2016 |
| ‘She gave it her best shot right away’: patient experiences of biomedical and patient-centered communication SL Swenson, P Zettler, B Lo Patient education and counseling 61 (2), 200-211, 2006 | 97 | 2006 |
| Toward coherent federal oversight of medicine PJ Zettler San Diego L. Rev. 52, 427, 2015 | 65 | 2015 |
| A new era in the ethics of human embryonic stem cell research B Lo, P Zettler, MI Cedars, E Gates, AR Kriegstein, M Oberman, ... Stem Cells 23 (10), 1454-1459, 2005 | 57 | 2005 |
| Closing the regulatory gap for synthetic nicotine products PJ Zettler, N Hemmerich, ML Berman Boston College law review. Boston College. Law School 59 (6), 1933, 2018 | 54 | 2018 |
| Is it cheating to use cheetahs: The implications of technologically innovative prostheses for sports values and rules PJ Zettler BU Int'l LJ 27, 367, 2009 | 53 | 2009 |
| 23andMe, the Food and Drug Administration, and the future of genetic testing PJ Zettler, JS Sherkow, HT Greely JAMA internal medicine 174 (4), 493-494, 2014 | 50 | 2014 |
| The strange allure of state “right-to-try” laws PJ Zettler, HT Greely JAMA internal medicine 174 (12), 1885-1886, 2014 | 42 | 2014 |
| Regulating genetic biohacking PJ Zettler, CJ Guerrini, JS Sherkow Science 365 (6448), 34-36, 2019 | 40 | 2019 |
| Implementing a public health perspective in FDA drug regulation PJ Zettler, MF Riley, AS Kesselheim Food & Drug LJ 73, 221, 2018 | 36 | 2018 |
| Promoting patient interests in implementing the Federal Right to Try Act HF Lynch, PJ Zettler, A Sarpatwari JAMA 320 (9), 869-870, 2018 | 29 | 2018 |
| Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products N Cuende, R Ciccocioppo, M Forte, J Galipeau, L Ikonomou, BL Levine, ... Cytotherapy 24 (7), 686-690, 2022 | 28 | 2022 |
| Is it ‘gene therapy’? JS Sherkow, PJ Zettler, HT Greely Journal of Law and the Biosciences 5 (3), 786-793, 2018 | 28 | 2018 |
| The Indirect Consequences of Expanded Off-Label Promotion PJ Zettler Ohio St. LJ 78, 1053, 2017 | 28 | 2017 |
| Diy crispr CJ Guerrini, GE Spencer, PJ Zettler NCL Rev. 97, 1399, 2018 | 27 | 2018 |
| From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy S Shah, P Zettler Yale J. Health Pol'y L. & Ethics 10, 135, 2010 | 27 | 2010 |
| Regulatory flexibility for COVID-19 research H Fernandez Lynch, NW Dickert, PJ Zettler, S Joffe, EA Largent Journal of Law and the Biosciences 7 (1), lsaa057, 2020 | 26 | 2020 |
